All In Biotech

Drug Trial Radar · NCT04982692

A Clinical Study of INTRAROSA® (Prasterone) Vaginal Inserts in Postmenopausal Vulvovaginal Atrophy

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase Ⅲ, Efficacy and Safety Study of INTRAROSA® (Prasterone) Vaginal Inserts on Postmenopausal Vulvovaginal Atrophy (VVA)

Last checked: Nov 20, 2026Latest source record: Oct 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 417 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

417

Actual

Start

Sep 13, 2021

Primary completion

Jan 30, 2023

Study completion May 8, 2023

Sponsor

Lead sponsor
Lee's Pharmaceutical LimitedIndustry
Sponsor type
Industry
First posted
Jul 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a phase III which includes two treatment phases. The phase 1 study is a multi-center, randomized, double-blind, placebo- controlled, parallel group that provide primary efficacy and safety data. The Phase 2 study is a single-arm, open-label conducted in a subset of subjects who completed the phase 1 study to provid additional long-term safety and efficacy.

Conditions

  • Postmenopausal Vulvovaginal Atrophy

Interventions

  • intravaginal prasteroneDrug

    6.5 mg of Intravaginal prasterone once daily at bedtime with a finger to insert the vaginal suppository into the vagina for a treatment cycle of 12 weeks.

  • Placebo ovulesDrug

    Placebo ovules once daily at bedtime with a finger to insert the vaginal suppository into the vagina for a treatment cycle of 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The change in the dyspareunia (dyspareunia) severity score at Day 85.Time frame: week 12
  2. The change in the vaginal pH at Day 85.Time frame: week 12
  3. The change in the proportion of parabasal cells at Day 85.Time frame: week 12
  4. The change in the proportion of superficial cells at Day 85.Time frame: week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Obstetrics and Gynecology Hospital of Fudan University

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.